In November it was learned that the government had agreed with that company to purchase 2 million doses of the drug, the amount is not detailed
The National Directorate of Medicines (DNM) today authorized the import, distribution and use of the vaccine against Covid-19 from AstraZeneca company, based in Cambridge, UK.
According to the DNM statement, it is a “special emergency permit” and was granted today at an extraordinary session.
It may interest you: The government must report on the risks and benefits of vaccines against COVID-19
In addition, the regulatory body justifies that the authorization granted for the drug is technically and legally supported by the evidence generated by the manufacturer and by the health authorities of other countries that have previously issued emergency authorizations for that product.
The most recent official figures account for 45,960 confirmed cases of patients with Covid-19; 1,327 deaths are also reported.
At the end of November, it was announced that the government had approved the purchase of 2 million doses of the covid-19 vaccine developed by AstraZeneca and the University of Oxford.
It may interest you: Medical College: The government has an agreement with Pfizer to use this vaccine in El Salvador
At the moment, the government has not made public the amounts involved in the purchase of any of these vaccines, only announcing that their application in the country will not incur additional costs to the population, and also each person can decide whether or not he accepts them. the injection.
The doubts of the specialists
The AstraZeneca company has yet to conduct additional studies to verify the efficacy and effectiveness of its COVID-19 vaccine, so it seems “impossible we will have it in El Salvador in the first quarter of the year,” infectologist Iván said Wednesday. . Solano Leiva, in an interview with Channel 33.
It may interest you: Infectologists are asking for more support from UES to investigate the new variant of COVID-19
The application of the AstraZeneca in the first quarter of 2021 was an announcement by the President of the Republic, Nayib Bukele, last November, although the president explained that this agreement was contingent on the company completing clinical trials on thousands of patients.
Specialist Solano Leiva confirmed that, as a member of the Advisory Committee on Immunization Practices (CAPI) working with the Ministry of Health, he knows that the Salvadoran government received technical approval to use the vaccine last Wednesday. Pfizer BionTech in the country, as Dr. Milton Brizuela, President of the Medical College, had told El Diario de Hoy.
The situation of slowdown AstraZeneca is going through prompted the government to negotiate with BionTech Pfizer, Solano Leiva said, adding that “this is more likely we can get it in the first quarter of 2021,” as expected by the executive branch, but with the British-Swedish medication with which he had already negotiated.
